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Abstract
Background: Current recommendations to prevent malaria in African pregnant women rely on insecticide treated nets
(ITNs) and intermittent preventive treatment (IPTp). However, there is no information on the safety and efficacy of their
combined use.
Methods: 1030 pregnant Mozambican women of all gravidities received a long-lasting ITN during antenatal clinic (ANC)
visits and, irrespective of HIV status, were enrolled in a randomised, double blind, placebo-controlled trial, to assess the
safety and efficacy of 2-dose sulphadoxine-pyrimethamine (SP). The main outcome was the reduction in low birth weight.
Findings: Two-dose SP was safe and well tolerated, but was not associated with reductions in anaemia prevalence at
delivery (RR, 0.92 [95% CI, 0.79–1.08]), low birth weight (RR, 0.99 [95% CI, 0.70–1.39]), or overall placental infection
(p = 0.964). However, the SP group showed a 40% reduction (95% CI, 7.40–61.20]; p = 0.020) in the incidence of clinical
malaria during pregnancy, and reductions in the prevalence of peripheral parasitaemia (7.10% vs 15.15%) (p,0.001), and of
actively infected placentas (7.04% vs 13.60%) (p = 0.002). There was a reduction in severe anaemia at delivery of borderline
statistical significance (p = 0.055). These effects were not modified by gravidity or HIV status. Reported ITN’s use was more
than 90% in both groups.
Conclusions: Two-dose SP was associated with a reduction in some indicators, but these were not translated to significant
improvement in other maternal or birth outcomes. The use of ITNs during pregnancy may reduce the need to administer
IPTp. ITNs should be part of the ANC package in sub-Saharan Africa.
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Introduction
Every year 50 million women become pregnant in areas where
malaria is endemic, and at least half of them live in Africa [1].
Malaria during pregnancy is associated with maternal and foetal
morbidity and mortality through maternal anaemia, low birth
weight (LBW) and premature delivery [2–6]. Thus, prevention of
malaria during pregnancy is a public health priority, particularly
in sub-Saharan Africa.
Currently, prevention of malaria in pregnancy in Africa relies
on intermittent preventive treatment (IPTp) and insecticide treated
nets (ITNs) [1]. ITNs are associated with significant health benefits
for both the mother and the newborn in sub-Saharan Africa [7].
IPTp entails the provision of an antimalarial at treatment doses
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irrespective of the presence of parasites or symptoms. The
currently recommended regimen for IPTp is at least 2 treatment
courses of SP given from the 2nd trimester onwards at least one
month apart [1].
Although IPTp and ITNs have shown separately to be
efficacious in reducing the harmful effects of malaria during
pregnancy, limited information exists on the safety and efficacy of
both interventions together [8,9].
IPTp, is now being implemented throughout most malaria
endemic areas of Africa, and has become somewhat controversial.
This is fuelled by two elements; on the one hand, the spread of SP
resistance, and the other, the overlap in some areas of malaria
transmission and high HIV prevalence. IPTp with SP is not
recommended to HIV-positive women receiving cotrimoxazole
prophylaxis or antiretroviral drugs [10]. Thus, although HIV-
positive women have an increased risk of malaria [11], current
recommendations may fail to provide them adequate protection.
In order to evaluate the safety and efficacy of two intermittent
doses of SP in women of all parities and regardless of HIV status,
who had been given a long-lasting ITN (LLITN) through the
antenatal clinic (ANC), we carried out a randomised, double blind,
placebo-controlled trial of IPTp in Mozambican pregnant women.
This information should help guide policy towards the rational use
of control tools for malaria prevention in pregnancy.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Study area and population
The study was undertaken at the Centro de Investigac¸a˜o em
Sau´de da Manhic¸a (CISM) in Manhic¸a District, southern
Mozambique. A demographic surveillance system covering 36
000 inhabitants is carried out by the CISM and constitutes the
study area. Adjacent to the CISM is the Manhic¸a District
Hospital (MDH), a 110 bed health facility. The characteristics of
the area have been described in detail elsewhere [12]. Perennial
malaria transmission with some seasonality is mostly attributable
to P falciparum. Anopheles funestus is the main vector, and the
estimated entomological inoculation rate for 2002 was 38
infective bites per person per year. Data on the efficacy of SP
in children in this area showed a therapeutic efficacy rate of
83%, with an in vivo parasitological sensitivity of 78.6% at day 14
[13]. Eighty percent of pregnant women have an institutional
delivery. During the study, malaria control in pregnancy relied
exclusively upon case management.
Figure 1. Trial profile. There were 3 and 7 twins births in the SP and placebo groups respectively. There was one triplet birth in the SP Group.*
sulphadoxine-pyrimethamine ** 1 woman in the SP group and 2 in the placebo group had a miscarriage before receiving dose 1
doi:10.1371/journal.pone.0001934.g001
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Study design
This double blind, individually randomised, placebo controlled
trial had the primary objective of estimating the additive protective
effect of two-dose IPTp with SP to that of ITNs on LBW
prevalence. Based on previous estimates in the area, a LBW
prevalence of 20% and an estimated 25% reduction to 15% in the
presence of ITNs [14], 411 women per group were needed to
show a lack of difference between the two groups with a
confidence interval of 7 (8% to 22%), at the 5% level of
significance with a 80% statistical power. The study protocol was
approved by the National Mozambican Ethics Review Commit-
tee, and the Hospital Clinic of Barcelona Ethics Review
Committee.
Enrolment and interventions
From August 2003 to April 2005 pregnant women were
enrolled at the MDH ANC if their gestational age was #
28 weeks, they did not report allergies to sulpha drugs, and they
were permanent residents of the CISM study area. After written
informed consent was obtained, the lowest available study number
was assigned. A computer-generated sequential list contained the
study numbers linked to treatment identification letters, randomly
ordered in blocks of 10. Tablets of SP or placebo, identical in
shape and colour, were stored in 10 bottles labelled only with a
single treatment identification letter. Women were randomised to
receive 3 tablets of SP (1500 mg sulphadoxine/75 mg pyrimeta-
mine) or placebo. The project health nurse administered study
drugs to women with at least 12 weeks of gestational age. Doses
were given twice from the second trimester, at least one month
apart. Regardless of their gestational age, all women at
recruitment received a LLITN. Assessment of gestational age
was made by bimanual palpation of the fundal height. Haemo-
globin and the rapid plasma reagin test (RPR, Syphacard,
Wellcome, USA) were assessed as part of the routine antenatal
care. In accordance to the National Programme for HIV control,
women were offered voluntary counselling and testing; HIV
positive women and their babies were given Nevirapine prophy-
laxis and referred for further clinical follow-up.
Follow-up
Plastic photo cards of mother and child facilitated identification
at every contact throughout the study (from recruitment until
8 weeks postpartum). A health facility-based, passive surveillance
system was established at the MDH. At each consultation, a
standardized questionnaire was completed documenting signs and
symptoms. Blood films were prepared for malaria parasite
Table 1. Characteristics of the study women at recruitment.
Placebo SP*
(n = 515) (n = 515)
Mean (SD) { Mean (SD) { p-value
Age (years) 24.31 (6.55) 24.00 (6.60) 0.366
Parity 3.12 (2.00) 3.09 (1.99) 0.809
Height (cm) 158.00 (5.63) 157.24 (5.99) 0.030
Haemoglobin (gr/dl) 10.93 (1.21) 10.97 (1.26) 0.742
n (%) n (%)
Gestational age (weeks) { 1st term 4 (1) 3 (1) 0.294
2nd term 291 (57) 315 (61)
3rd term 220 (43) 197 (38)
Gravidity primigravidae 129 (25) 137 (27) 0.821
1 to 3 pregnancies 205 (40) 204 (40)
4 or . pregnancies 181 (35) 174 (34)
HIV test negative 338 (66) 324 (63) 0.107
positive 91 (18) 117 (23)
not done 1 86 (17) 74 (14)
MUAC index (cm) " normal .22 396 (98) 401 (98) 0.475
#22 10 (2) 7 (2)
Literacy reads and/or writes 212 (41) 213 (41) 0.346
neither reads nor writes 300 (58) 302 (59)
unknown 3 (1) 0 (0)
RPR Syphilis test ** positive 72 (14) 50 (10) 0.034
negative 442 (86) 465 (90)
unknown 1 (0) 0 (0)
*sulphadoxine-pyrimethamine
{stardard deviation
{1st term: 0–12 weeks, 2nd term: 13–24 weeks,3rd term: 25–40 weeks
1Refused voluntary testing
"Mid-upper arm circunference
**Rapid plasma reagin
doi:10.1371/journal.pone.0001934.t001
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examination and the packed cell volume (PCV) measured if there
was a history of fever in the preceding 24 hrs, or the axillary
temperature was $37.5uC. Clinical malaria episodes were treated
with chloroquine or SP in the first and subsequent trimesters,
respectively, for uncomplicated malaria, and parenteral quinine
for severe malaria.
At delivery, venous blood was collected by venipuncture from
the mother and the umbilical cord, and two thick blood smears
and a filter paper prepared for haematological and parasitological
determinations. Newborns were weighed on a digital scale,
accurate to the nearest gram. The gestational age was assessed
by the Dubowitz’s method [15]. A placental biopsy was collected
and two impression smears and blood placed onto filter paper
were prepared from a placental biopsy sample.
Eight weeks after delivery a capillary blood sample was collected
from the mother and the infant for parasite and haematological
determinations. The axillary temperature was measured and the
weight of the baby recorded.
ITN use was assessed by asking the women if they had slept
under the LLITN the night before.
Laboratory Methods
Thick and thin blood films were stained and read according to
standard, quality-controlled procedures [16,17]. PCV was measured
in a microcapillary tube after centrifugation. Blood samples were
centrifuged and the plasma and erythrocyte pellets stored at270uC.
HIV serostatus was assessed using a rapid test (Determine,
Abbot Laboratories, USA), and positive results confirmed using
Unigold rapid test (TM HIV, Trinity Biotech, Ireland).
Tissue samples were collected from the maternal side of the
placentas and placed into 10% neutral buffered formalin. Biopsies
were processed and stained following standard procedures [18].
Impression smears from the placenta, were stained with Giemsa
and read following standard procedures [19].
Data Management, Statistical Methods and Definitions
Data were analysed by intention-to-treat (ITT) analysis whereby
all randomised women were included regardless of whether or not
they had received the intervention and the number of doses.
The risk of the first or only episode of clinical malaria between
recruitment and 8 weeks postpartum, or censoring due to
withdrawal or death, was estimated using Cox regression models.
The protective effect (PE) of SP was estimated from the hazard
ratio (HR) as PE = 100(1-HR) %.The effect of time on efficacy
since dose 1 was estimated using time versus treatment interaction
in a Cox time-dependent model. In the secondary analyses, crude
and adjusted (for parity, HIV status and baseline variables)
prevalences were calculated using the Risk Ratio. Likelihood Ratio
tests were calculated to evaluate the interaction between the
intervention group and parity, or HIV status. Differences in
prevalence were estimated with the x2 test and proportions with
the Fisher’s exact test. Continuous values were evaluated with the
non-parametric Wilcoxon test. Data analysis was performed using
Stata 8.2 (Stata Corporation, College Station, TX, USA).
Malaria infection was defined as the presence of asexual P.
falciparum parasites of any density in a blood smear. A clinical
malaria episode was defined as the latter plus an axillary
temperature $37.5uC. The duration of a malaria episode was
estimated as 28 days. Overall and severe anaemia were defined as
a PCV lower than 33% and 21%, respectively.
Placental infection was classified according to a previous
definition [20]. Any placental infection was defined as the
presence of parasites and/or pigment in the histological exami-
nation, and/or in the impression smear.
Table 2. Safety of SP* during the study {.
Placebo+ITNs SP*+ITNs
Safety in the mother episodes Rate episodes Rate RR (95% CI) { p-value
Incidence of all hospital admissions during pregnancy 54 0.35 52 0.32 0.89 (0.61,1.30) 0.539
Incidence of outpatient visits during pregnancy 345 1.83 327 1.64 0.94 (0.81,1.10) 0.444
Incidence of all hospital admissions during post-partum 17 0.30 20 0.35 1.06 (0.56,2.03) 0.856
Incidence of outpatient visits during post-partum 38 0.68 39 0.69 0.92 (0.59,1.43) 0.697
n/N (%) n/N (%) total
Skin reactions 1 4/515 (0.77) 5/515 (0.97) 9 1.000
Maternal deaths 0/515 (0.00) 1/515 (0.19) 1 1.000
Placebo+ITNs SP*+ITNs
Safety in the infant episodes Rate episodes Rate RR (95% CI) { p-value
Incidence of all hospital admissions 25 0.46 25 0.45 0.93 (0.53,1.61) 0.786
Incidence of all outpatients visits 54 1.00 64 1.16 0.77 (0.54,1.11) 0.164
n/N (%) n/N (%) total
Infant deaths 11/503 (2.18) 6/514 (1.16) 17 0.089
*Sulphadoxine-pyrimethamine
{From recruitment up to 2 months after delivery
{Confidence interval
1Within 27 days after any IPTp doses
doi:10.1371/journal.pone.0001934.t002
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Women with a multiple delivery (twins or triplets) were also
included in the analysis.
Results
Baseline characteristics of study women
Figure 1 shows the trial profile and table 1 shows the baseline
characteristics of participants. Reported ITN use at the end of
pregnancy was similar between the groups (90.38% and 92.52% in
the SP and placebo groups, respectively, p = 0.324). 85% of the
women had an HIV test and 23.6% were HIV positive. Mean
gestational age was 23.21 (SD 3.44) weeks at the first IPTp SP/
placebo dose and 28.34 (SD 3.65) weeks at the second IPTp dose.
Mean time between first and second IPTp SP/placebo dose was
36.53 (SD 11.55) days, and mean time between last dose and
delivery was 76.91 (SD 31.19) days.
Safety and morbidity
Only one woman from the SP group vomited after IPTp dose 1.
There were no differences in the incidence of hospital admissions
and outpatient visits during pregnancy or postpartum period, or in
infant visits until age 8 weeks. Nine women, similarly distributed
between the groups, had mild skin reactions within 27 days after
any IPTp dose (table 2). No severe skin reactions were reported.
There was one maternal death (SP group), who died of obstetric
causes. There were 6 infants deaths in the SP group and 11 in the
placebo group (p = 0.089). There was one newborn with a major
congenital malformation (spina bifida) in the SP group.
Effect of SP plus ITNs on main outcomes
There were no significant differences between the intervention
groups in either the prevalence of LBW (RR, 0.99 [95% CI, 0.70–
1.39];p = 0.940) (table 3) or in mean birth weight [3033.0 (SD
477.1) in the SP group, 3003.5 (SD 522.6) in the placebo group;
p = 0.637] (table 3). SP was associated with a statistically significant
reduction in the prevalence of LBW in women with $4
pregnancies in the subgroup analysis. Similarly, there were no
significant differences between the two groups in either the
prevalence of prematurity (RR, 0.74 [95% CI, 0.39–
1.43];p = 0.372), or the mean gestational age [39.7 weeks (SD
Table 3. Low birth weight and secondary fetal and neonatal outcomes. Crude and adjusted effect by gravidity and HIV status.
Placebo+ITNs SP*+ITNs
n/N (%) n/N (%) RR (95% CI) { p-value
Low birth weight (,2500 gr) {
crude analysis 59/496 (11.90) 58/494 (11.74) 0.99 (0.70–1.39) 0.940
adjusted by gravidity 0.96 (0.67–1.38) 0.828
adjusted by HIV status 0.98 (0.68–1.40) 0.900
Low birth weight (,2500 gr) by gravidity
Primigravidae 25/121 (20.66) 29/133 (21.80) 1.06 (0.66–1.70) 0.824
1 to 3 pregnancies 13/195 (6.67) 20/194 (10.31) 1.55 (0.79–3.02) 0.197
4 or more pregnancies 21/180 (11.67) 9/167 (5.39) 0.46 (0.22–0.98) 0.038
Low birth weight (,2500 gr) by HIV status
Negative 38/327 (11.62) 34/313 (10.86) 0.93 (0.60–1.45) 0.762
Positive 10/85 (11.76) 17/112 (15.18) 1.29 (0.62–2.67) 0.490
Not done 1 11/84 (13.10) 7/69 (10.14) 0.77 (0.32–1.89) 0.573
Pre-term birth (,37 weeks) 20/407 (4.91) 15/411 (3.65) 0.74 (0.39–1.43) 0.372
Cord blood parasitaemia 5/435 (1.15) 4/435 (0.92) 0.80 (0.22–2.96) 0.738
Cord blood anaemia (PCV,37%) " ** 45/435 (10.34) 22/435 (5.06) 0.49 (0.30–0.80) 0.004
Quantitative variables (Mean (SD))
Birth weight 3003.55 (522.69) 3033.00 (477.11) 0.637
Newborn gestational age (weeks) 39.55 (1.49) 39.70 (1.31) 0.081
Cord blood PCV (%) 44.05 (7.49) 45.06 (7.88) 0.003
Pregnancy outcomes n % n %
Spontaneous abortions (birth weight,500gr) 6 1 4 1 0.753
Stillbirths (birth weight $500gr) 11 2 14 3 0.686
Early neonatal deaths (,8 days of life) 5 1 0 0 0.062
Perinatal deaths (Stillbirths and early neonatal deaths) 16 3 14 3 0.716
Late neonatal deaths (.8 and ,29 days of life) 0 0 2 0 0.500
*Sulphadoxine-pyrimethamine
{Confidence interval
{Interaction between group and gravidity, p = 0.061; Interaction between group and HIV status, p = 0.682
1Refused voluntary testing
"Packed-cell volume
**Interaction between group and gravidity, p = 0.626; Interaction between group and HIV status, p = 0.191
doi:10.1371/journal.pone.0001934.t003
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1.31) in the SP group, 39.5 weeks (SD 1.49) in the placebo group;
p = 0.081) (table 3). Adjustment by confounding variables did not
modify these results.
The risk of foetal anaemia was halved among women in the SP
group compared to those who received placebo (RR, 0.49 [95%
CI, 0.30–0.80]; p = 0.003) (table 3). A non-statistically significant
reduction in the number of early neonatal deaths was found
among women receiving SP (p = 0.062) (table 3).
Overall, 7% of the women receiving two-dose SP and 10%
receiving placebo had a first or only episode of uncomplicated
malaria (protective efficacy (PE), 40% [95% CI, 7.40–61.20];
p = 0.020) (figure 2). The analysis of the incidence of clinical
malaria within the month after each SP dose showed a PE of
74.1% (95% CI, 30.8–90.3; p = 0.003) after dose 1 and of 71.4%
(95% CI, 13.10–90.60; p = 0.015) after dose 2.
There was no difference in the prevalence of anaemia at
delivery between the intervention and control groups (RR, 0.92
[95% CI, 0.79–1.08]; p = 0.309). However, although not signifi-
cantly, there were fewer women in the IPTp/SP than in the
placebo group with severe anaemia at delivery (RR, 0.25 [95% CI,
0.05–1.16]; p = 0.055). This difference was not modified by
adjustments for gravidity and HIV status (table 4).
Table 4 shows the effect of IPTp on maternal parasitological
endpoints. Peripheral parasitaemia was significantly lower among
women in the SP group (7.10%, 35/493) compared to the placebo
(15.15%, 75/495) (RR, 0.47 [95% CI, 0.32–0.69]; p = 0.000). This
result was not modified by gravidity or HIV status.
Prevalence of any placental infection was comparable between
the groups (RR, 1.00 [95% CI, 0.88–1.13]; p = 0.964), and so it
was the proportion of placentas with only pigment deposition on
histology (past infection). However, there were significantly less
infected placentas with parasites in the SP group as assessed by
impression smears (RR, 0.52 [95% CI, 0.34–0.79]; p = 0.002) or
histology (acute and chronic infection) (table 4). This difference in
the proportion of actively infected placentas was mainly accounted
for the HIV positive women [6.12% (6/98) in the SP group versus
24.32% (18/74) in the placebo group; p = 0.001].
There were less women in the SP group than in the placebo
group with malaria parasitaemia at 8 weeks after delivery (RR,
0.52 [95% CI, 0.27–0.99]; p = 0.044). There were no differences
in the prevalence of women or infants with clinical malaria or
anaemia (table 5). Similarly, there were no differences in the
incidence of outpatient attendances or hospital admissions with
malaria in either mothers or infants during the post-partum period
(data not shown).
Discussion
This randomised placebo-controlled trial of IPTp in Mozambi-
can pregnant women has shown that administering two IPTp-SP
doses to women concurrently using LLITNs was safe and well
tolerated, and there were no significant drug reactions despite the
high prevalence of HIV among the study women. The
intervention was associated with a moderate reduction in the
incidence of clinical malaria during pregnancy, and with a
statistically significant reduction in the prevalence of parasitaemia
at delivery and at 8 weeks postpartum. However, these positive
effects did not appear to translate in an improvement on relevant
foetal birth outcomes such as birth weight or prematurity, nor on
maternal anaemia.
It could be argued that parasite resistance to SP may explain the
modest impact on some malariometric parameters and the lack of
effect on the more significant birth outcomes. The available in vivo
drug efficacy data in children in this area showed a parasitological
sensitivity of 78,6% at day 14 [13], but the study was carried out
3 years before the start of the trial. Drug resistance can evolve
quite rapidly, and it may be that by the time the study started, the
true resistance level may have been higher. However, there is
evidence that strongly suggests that SP was highly effective in the
area during the study. SP was highly efficacious in participants for
malaria prevention during the 30 days following each dose. A very
similar effect was seen in a concurrent study of IPT in infants in
the same area, whereby the efficacy of SP for malaria prevention
varied between 60% and 90% in the month after SP administra-
Figure 2. Intention to treat cohort. First or only episode of clinical malaria from IPTp dose 1 until delivery
doi:10.1371/journal.pone.0001934.g002
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tion [21, C. Mene´ndez et al., unpublished]. Furthermore, an
ongoing study of placental malaria in this area has documented a
sharp fall in the prevalence of placental infection following
programme implementation of IPTp with SP in Mozambique (A.
Mayor et al., unpublished). It is important to better understand the
relationships between the assessment of in vivo drug resistance in
sick children and the use of the same drug for prevention in
asymptomatic individuals [22].
The risk of malaria during pregnancy seems to concentrate in
primi and secundigravidae women [8,23–27], and consequently
previous IPTp studies have been carried out only in this
population. There are two main reasons why we need to re-
consider this approach. Firstly, targeting a specific group of
women may prove difficult when scaling up this intervention to
programme conditions. Secondly, our results suggest that in the
presence of ITNs the effect of SP is independent of gravidity.
As previously reported, SP reduced the prevalence of malaria
parasitaemia at delivery and post-partum [2,9]. However, this
reduction was not associated with a corresponding effect on the
prevalence of anaemia. In this study, the prevalence of severe
anaemia at delivery was much lower than expected, probably due
to the effect of ITNs [14]. This might explain the insufficient
power to see an effect of IPTp on this morbidity outcome.
However, no effect was observed either in the prevalence of overall
Table 4. Severe anaemia and parasitological outcomes at delivery. Crude and adjusted effect by gravidity and HIV status.
Placebo+ITNs SP*+ITNs
n/N (%) n/N (%) RR (95% CI) p-value
Severe anaemia (PCV ,21%) { {
Crude analysis 8/495 (1.62) 2/493 (0.41) 0.25 (0.05–1.16) 0.055
adjusted by gravidity 0.25 (0.05–1.16) 0.077
adjusted by HIV status 0.24 (0.05–1.13) 0.070
Severe anaemia (PCV ,21%) by gravidity
Primigravidae 3/127 (2.36) 0/133 (0.00) 0.00 (.-.) 0.072
1 to 3 pregnancies 3/193 (1.55) 1/192 (0.52) 0.33 (0.03–3.16) 0.312
$4 pregnancies 2/175 (1.14) 1/168 (0.60) 0.51 (0.05–5.63) 0.579
Severe anaemia (PCV ,21%) by HIV status
Negative 5/324 (1.54) 1/311 (0.32) 0.21 (0.04–1.75) 0.108
Positive 2/87 (2.30) 1/112 (0.89) 0.39 (0.04–4.25) 0.424
Not done 1 1/84 (1.19) 0/70 (0.00) 0.00 (.-.) 0.351
Peripheral parasitaemia "
Crude analysis 75/495 (15.15) 35/493 (7.10) 0.47 (0.32–0.69) 0.000
adjusted by gravidity 0.46 (0.31–0.69) 0.000
adjusted by HIV status 0.47 (0.33–0.70) 0.000
Peripheral parasitaemia by gravidity
Primigravidae 30/127 (23.62) 18/133 (13.53) 0.57 (0.34–0.97) 0.036
1 to 3 pregnancies 31/193 (16.06) 12/192 (6.25) 0.39 (0.21–0.73) 0.002
$4 pregnancies 14/175 (8.00) 5/168 (2.98) 0.37 (0.14–1.01) 0.042
Peripheral parasitaemia by HIV status
Negative 43/324 (13.27) 22/311 (7.10) 0.53 (0.33–0.87) 0.010
Positive 17/87 (19.54) 6/112 (5.56) 0.27 (0.11–0.67) 0.002
Not done 1 15/84 (17.86) 7/70 (9.33) 0.56 (0.24–1.30) 0.165
Any placental malaria infection ** 219/419 (52.27) 222/426 (52.11) 1.00 (0.88–1.13) 0.964
Positive impression smears 57/419 (13.6) 30/426 (7.04) 0.52 (0.34–0.79) 0.002
Positive histology 213/419 (50.84) 218/426 (51.17) 1.01 (0.88–1.15) 0.922
Classification of placental infection by histology n/N (%) n/N (%)
acute 25/419 (5.96) 16/426 (3.75) 0.004
chronic 51/419 (12.17) 28/426 (6.57)
past 137/419 (32.69) 174/426 (40.84)
not infected 206/419 (49.16) 208/426 (48.82)
*Sulphadoxine-pirimethamine
{Packed-cell volume
{Interaction between group and gravidity, p = 0.409; Interaction between group and HIV status, p = 0.760
1Refused voluntary counselling and testing
"Interaction between group and gravidity, p = 0.622; Interaction between group and HIV status, p = 0.414
**Either histology or impression smear
doi:10.1371/journal.pone.0001934.t004
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anaemia, despite its much higher prevalence. Further studies are
needed to understand the lack of correlation between parasito-
logical and morbidity outcomes frequently observed in malaria
prevention trials during pregnancy.
The prevalence of active placental infection (i.e., containing
parasites) in the SP group (7% overall and 6% in the HIV-positive
women) was similar to the one reported in Kenyan and Malawian
HIV-positive women who received monthly SP (7.1% and 7.8%,
respectively) [23;26]. In these studies three or more SP doses were
needed to show a comparable impact in HIV-positive and
negative women. However, in these trials, ITNs were not provided
as part of the study. Our data suggest that two-dose SP may
protect against peripheral and placental parasitemia in HIV-
positive women if they use an ITN.
Despite the fact that bednets are not traditionally used in this
area, the delivery of ITNs through the ANC was well accepted and
the compliance with their use was very high.
In recent years, IPTp with SP has been the cornerstone of
malaria control in pregnant women living in stable transmission
areas. However, the recent controversy has raised questions as to
whether this was the most appropriate approach for malaria
prevention in African pregnant women given the reported
increased in parasite resistance to SP in some areas [22]. This
has led WHO to question the adequacy of this recommendation in
favour of other less well established strategies (such as indoor
residual spraying) [28]. Another line of discussion recommended
increasing the frequency of SP- IPTp to monthly doses to improve
its efficacy. This controversy comes at a time when most endemic
countries in Africa have already, or are in the process of,
implementing IPTp, with all the logistical and economic efforts
associated with the introduction of new public health measures in
developing countries.
In conclusion, this study provides information of public health
relevance in deciding the adequacy of adding IPTp when ITNs are
used, and suggests that IPTp may not be required if an ITN is used.
To confirm these findings, more studies of similar design are needed
in areas of different malaria endemicity in Africa. In the meantime,
efforts should be focused to promote the delivery of long-lasting ITNs
as part of other routine ANC health interventions.
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Table 5. Prevalence of parasitaemia and anaemia in the mother and infant at 2 months after delivery.
Placebo+ITNs SP*+ITNs
n/N (%) n/N (%) RR (95% CI) { p-value
Mother
P falciparum parasitaemia {
crude analysis 26/432 (6.02) 13/416 (3.13) 0.52 (0.27–0.99) 0.044
adjusted by gravidity 0.50 (0.25–0.97) 0.040
adjusted by HIV status 0.52 (0.27–1.01) 0.054
P falciparum parasitaemia by gravidity
Primigravidae 11/98 (11.22) 6/111 (5.41) 0.48 (0.18–1.25) 0.125
1 to 3 pregnancies 9/175 (5.14) 5/161 (3.11) 0.60 (0.21–1.76) 0.351
$4 pregnancies 6/159 (3.77) 2/144 (1.39) 0.37 (0.07–1.79) 0.196
P falciparum parasitaemia by HIV status
Negative 20/286 (6.99) 8/263 (3.04) 0.43 (0.19–0.97) 0.036
Positive 3/77 (3.90) 4/97 (4.12) 1.06 (0.24–4.59) 0.940
Not done 1 3/69 (4.35) 1/56 (1.79) 0.41 (0.04–3.84) 0.418
P falciparum parasitaemia+fever " 1/432 (0.23) 1/416 (0.24) 1.04 (0.06–16.55) 0.978
Overall anaemia (PCV,33%) ** 89/432 (20.60) 95/416 (22.84) 1.10 (0.85–1.42) 0.461
Infant
P falciparum parasitaemia 5/417 (1.20) 2/404 (0.50) 0.41 (0.08–2.12) 0.273
Overall anaemia (PCV,33%) ** 66/417 (15.83) 63/404 (15.59) 0.98 (0.71–1.34) 0.882
*Sulphadoxine-pyrimethamine
{Confidence interval
{Interaction between study group and gravidity, p = 0.876; Interaction between study group and HIV status, p = 0.575
1Refused voluntary testing
"Fever: Ta $37.5uC
**Packed-cell volume
doi:10.1371/journal.pone.0001934.t005
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